Avesthagen Limited launches nutritional botanical bioactive supplements

Integrated systems biology platform company Avesthagen Limited today announced the launch of seven new botanical bioactives under the Avestaä brand aimed at promoting wellness through prevention of specific degenerative conditions like diabetes, bone loss and cardiovascular diseases.

The bioActives will be available as dietary supplements appealing to the youthful as well as in cereal bars and cracker categories.
 
Avesthagen uses two of its patented technologies to develop the bioActives; Adeptä  a comprehensive database that brings together traditional medicine with modern systems biology and MetaGridä, a unique algorithm that enables comprehensive constituent profiling.

The metabolic fingerprints generated not only help chararacterise the bioActives but also help in quality control and assurance. The MetaGridä also helps maintain batch-to-batch reproducibility of the bioactive, which is an issue in conventional systems. Avesthagen uses cell-based assays and GLP-compliant pre clinical studies to ensure safety and efficacy of the bioActives. Organoleptic optimisation is done to improve the taste and other properties. The bioActives are manufactured in an ISO 9001:2000, ISO22000:2005 facility.
 
The bioActives launched include:
 
Bioactive  Benefits
Aspandä Controls Blood sugar
Teestarä Moderates blood sugar levels
Cincataä Maintains blood glucose levels
Bonapureä Promotes bone growth
Phytosseaä Assists in inhibiting cartilage degradation
Smartcholä Moderates cholesterol levels
Xanomaxä Has antioxidant properties
 
Speaking on the launch, Dr Villoo Morawala Patell, founder, chairperson and managing director of Avesthagen Limited, said, "We strongly believe that science and technology is the way to bring to the people the immense knowledge base of traditional medicine resulting in quality ingredients that add to taste and health needs. Avesthagen's goal is to incorporate great-tasting, life-enhancing natural ingredients into the world's lifestyle. We have extensively studied the market and our bionutrition development team has created bioactives with variants that hold tremendous uses for the consumer. These seven bioActives will be followed by many more that are in the pipeline."
 
Chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease in 2001. The proportion of the burden of these diseases is expected to increase to 57% by 2020.  This increase in the number of chronic diseases and degenerative conditions across the globe has spurred interest in these health-promoting ingredients.